Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors

Abstract

Sunitinib, Regorafenib and Masitinib may prove clinically useful in inhibiting breast cancer cell migration and metastasis while only Sunitinib (and possibly Regorafenib in some breast cancer subtypes) is effective at inhibiting both migration and proliferation of breast cancer cells.